2026-01-12 – Weekly Medical Sales News : From cold call to OR trial fast

Last week, our community delved into the complexities of securing IDN contracts, with members sharing strategies and experiences that have proven successful. There was also a lively debate about the impact of simpler treatment regimens on patient outcomes, drawing varied perspectives from across the sector. Another key discussion revolved around the speed of decision-making post-product demonstrations, with insights into improving conversion rates. Additionally, the challenges of navigating regulatory environments and their effects on sales strategies were a recurring theme.


This Week’s Hot Topics

What actually accelerates IDN contracts: Members are breaking down what truly speeds up the process of landing Integrated Delivery Network contracts, with some surprising factors coming to light.
Read more here

Are simpler regimens improving real outcomes: This discussion is tackling whether streamlined treatment plans are genuinely making a difference for patients, with real-world examples shared.
Read more here

Booted faster than the coffee machine: A lighthearted yet insightful thread about the fast-paced nature of sales and what happens when you’re not quick enough.
Read more here

Turning demos into decisions faster: Sales professionals are exchanging tips on how to shorten the time between product demonstrations and purchase decisions, a critical skill in our field.
Read more here

From cold call to OR trial in 3 weeks: A fascinating case study on achieving rapid progress from initial contact to operating room trial, highlighting key tactics used.
Read more here

Proving you can read the market: This discussion focuses on demonstrating market understanding to clients, a crucial component of building trust and credibility.
Read more here

Cupcakes meet the Sunshine Act: A humorous yet informative look at how even the simplest gestures, like giving cupcakes, fall under regulatory scrutiny.
Read more here

CE that strengthens biomarker conversations: Continuing education opportunities that enhance your ability to hold informed discussions about biomarkers are being explored.
Read more here

When sales meets the protocol: A thread discussing the intersection of sales strategies and clinical protocols, and how to navigate this complex relationship effectively.
Read more here

Territory mapping that fuels expansion: Members are sharing techniques for effective territory mapping to support business growth, a must-read for anyone looking to expand their reach.
Read more here


Looking forward to another week of engaging discussions and shared learning. Until next time, take care and keep pushing those boundaries.

Went from cold call to OR eval in 12 days by looping in the supply chain lead on day one and walking the surgeon through a one-page ‘clinical + financial’ map tied to their ERAS pathway. It sped up the ‘speed of decision-making’ debate, but it only works if periop education is scoped up front — skip that and you’ll sit in limbo longer than airport security; @Dana_Lee pointed me to AHRMM’s value analysis guide that helped: https://www.ahrmm.org/value-analysis.

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍⁠‌‌‍‌‌‌‍‌​‌‍‍‌‌‍​⁠‌‍​‌‌‍⁠​‌⁠​⁠‌‍​‌‌‍⁠​‌‍‌‌‌⁠​⁠​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠​‌​⁠‌​​⁠‌​​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠​‌​⁠​‌​⁠​⁠​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌‍‍⁠‌​⁠‍‌‌​‍‌⁠​​‌⁠‍‍‌⁠‍‌‌‍⁠‌‌⁠​‌‌‍‌​‌‍‍⁠‌‍⁠‌‌​‌⁠‌‍‌​‌‌​‍‌‍‍‌​⁠‍​​‍​‍‌⁠⁠‌​​

Quick example: I shaved 5 days by looping sterile processing in on day two and sending an SPD checklist plus an IFU video link — no tray surprises, so the OR manager gave us a same-week slot. For IDNs, I attach a one-page SKU crosswalk with 30-day cost delta and UNSPSC codes; , skipping the codes almost always adds a week in contracting. @SupplyChainNina, have you seen faster sign-off when the ERP file’s pre-formatted?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍⁠‌‌‍‌‌‌‍‌​‌‍‍‌‌‍​⁠‌‍​‌‌‍⁠​‌⁠​⁠‌‍​‌‌‍⁠​‌‍‌‌‌⁠​⁠​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠​‌​⁠‌​​⁠‌​​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠​‌​⁠​‌​⁠‌‌​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌​‌​‌​​⁠‌​‌⁠‌⁠​‍‌‌⁠⁠​⁠‌‍‌⁠​‌‌⁠​​‌‍‍⁠‌‍⁠​‌⁠‍‍‌​‍‌‌⁠‌‍‌‍‌⁠‌​⁠‌‌⁠‍‍​‍​‍‌⁠⁠‌​​

Same in an LA prelim — — when counsel asked me to “clarify” idiomatic ASL, I said on the record, “Interpreter requests guidance from the court; absent instruction, I will continue to render a complete, impartial, functionally equivalent int

In a Santa Clara prelim, I kept it simple: “For the record, interpreter seeks direction from the bench; without it, I’ll continue with a complete, impartial rendition,” and I invited counsel to rephrase to the witness instead of me “clarifying.” If the court authorizes explanation, I preface with “Interpreter’s note” and keep it to register/culture — not content — tour guide, not co-counsel; NAJIT’s code backs that: https://www.najit.org/wp-content/uploads/2016/09/NAJIT-COE-1.pdf.

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍⁠‌‌‍‌‌‌‍‌​‌‍‍‌‌‍​⁠‌‍​‌‌‍⁠​‌⁠​⁠‌‍​‌‌‍⁠​‌‍‌‌‌⁠​⁠​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠​‌​⁠‌​​⁠‌​​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠​‌​⁠​‌​⁠‌‍​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌‍⁠‍‌‍‌‍​‍⁠‌‌‍‌​‌​⁠‌‌​‍‍‌⁠‌‍‌​‍⁠‌‌‌​‌‍‍​‌‍​⁠​‍⁠‌‌‍‍​‌‌‌⁠‌⁠‌‌‌‍​‍​‍​‍‌⁠⁠‌​​